From preclinical research through clinical development, we’re here to help you at every stage of the continuum to deliver accurate, on-time results and advance your program. To meet your program’s requirements, our GLP, nonproprietary methods have been developed according to FDA Crystal City and current regulatory guidelines. You’ll benefit from our expert scientific team and state-of-the-art technologies to support your DDI, concomitant drugs and generics studies.
For your convenience, we’ve organized our nonproprietary bioanalytical methods into two categories: single analyte methods and multi-analyte methods, accessible in the PDFs below. These lists now include therapeutic area and disease.